Roche, Pfizer and Novartis earn top marks from cancer patient groups during pandemic: survey

The pandemic colored most opinions last year—including patient opinions about pharma. Cancer patients, often sidelined at home during the crisis, were paying particularly close attention to pharma company actions.

The good news is that pharma generally fared well with cancer patients during the pandemic. Fifty-eight percent of advocacy groups rated pharma's reputation as excellent or good in 2020, a slight increase from 54% during the previous year, according to a new survey from PatientView.